The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Decreased tumor surveillance in perforin-deficient mice.
Open accessAbstract
Immune surveillance against tumors usually depends on T cell recognition of tumor antigens presented by major histocompatibility complex (MHC) molecules, whereas MHC class I- tumors may be controlled by natural killer (NK) cells. Perforin-dependent cytotoxicity is a major effector function of CD8+ MHC class I-restricted T cells and of NK cells. Here, we used perforin-deficient C57BL/6 (PKO) mice to study involvement of perforin and Fas ligand in tumor surveillance in vivo. We induced tumors in PKO and normal C57BL/6 mice by (a) injection of different syngeneic tumor cell lines of different tissue origin in naive and primed mice; (b) administration of the chemical carcinogens methylcholanthrene (MCA) or 12-O-tetradecanoylphorbol-13-acetate (TPA) plus 7,12-dimethylbenzanthracene (DMBA), or (c) by injection of acutely oncogenic Moloney sarcoma virus. The first set of models analyzes the defense against a tumor load given at once, whereas the last two sets give information on immune defense against tumors at the very moment of their generation. Most of the tumor cell lines tested were eliminated 10-100-fold better by C57BL/6 mice in an unprimed situation; after priming, the differences were more pronounced. Lymphoma cells transfected with Fas were controlled 10-fold better by PKO and C57BL/6 mice when compared to untransfected control cells, indicating some role for FasL in tumor control. MCA-induced tumors arose more rapidly and with a higher incidence in PKO mice compared to C57BL/6 or CD8-deficient mice. DMBA+TPA-induced skin papillomas arose with similar high incidence and comparable kinetics in both mouse strains. C57BL/6 and PKO mice have a similar incidence of Moloney murine sarcoma and leukemia virus-induced sarcomas, but tumors are larger and regression is retarded in PKO mice. Thus, perforin-dependent cytotoxicity is not only a crucial mechanism of both cytotoxic T lymphocyte- and NK-dependent resistance to injected tumor cell lines, but also operates during viral and chemical carcinogenesis in vivo. Experiments addressing the role of Fas-dependent cytotoxicity by studying resistance to tumor cell lines that were stably transfected with Fas neither provided evidence for a major role of Fas nor excluded a minor contribution of Fas in tumor surveillance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement
Shinkai, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90029-c · Cited by 2,150
Kägi, D., Ledermann, B., Bürki, K., Seiler, P., Odermatt, B., Olsen, K. J., Podack, E. R., Zinkernagel, R. M., & Hengartner, H. (1994) · Nature · doi:10.1038/369031a0 · Cited by 1,757
Self-citationFas and Perforin Pathways as Major Mechanisms of T Cell-Mediated Cytotoxicity
Kägi, D., Vignaux, F., Ledermann, B., Bürki, K., Depraetere, V., Nagata, S., Hengartner, H., & Golstein, P. (1994) · Science · doi:10.1126/science.7518614 · Cited by 1,516
Self-citationThe Role of the CD28 Receptor During T Cell Responses to Antigen
Linsley, P. S., & Ledbetter, J. A. (1993) · Annual Review of Immunology · doi:10.1146/annurev.iy.11.040193.001203 · Cited by 1,298
Immunity to Methylcholanthrene-Induced Sarcomas
(1957) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,229
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
Lowin, B., Hahne, M., Mattmann, C., & Tschopp, J. (1994) · Nature · doi:10.1038/370650a0 · Cited by 1,051
Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., & Linsley, P. S. (1992) · Cell · doi:10.1016/s0092-8674(05)80059-5 · Cited by 1,050 · cited 1×
“, B7, intracellular adhesion molecule-I, and LFA-3) has been shown to dramatically increase the efficiency of prinung in certain instances (4-7).”
BackgroundTherapy with monoclonal antibodies by elimination of T-cell subsets in vivo
Cobbold, S. P., Jayasuriya, A., Nash, A., Prospero, T. D., & Waldmann, H. (1984) · Nature · doi:10.1038/312548a0 · Cited by 863
Greenberg, P. D. (1991) · Advances in Immunology · doi:10.1016/s0065-2776(08)60778-6 · Cited by 603
Schrier, P. I., Bernards, R., Vaessen, R. T. M. J., Houweling, A., & van der Eb, A. J. (1983) · Nature · doi:10.1038/305771a0 · Cited by 559
Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo
Pircher, H., Moskophidis, D., Rohrer, U., Bürki, K., Hengartner, H., & Zinkernagel, R. M. (1990) · Nature · doi:10.1038/346629a0 · Cited by 555
Self-citationCD8 is needed for development of cytotoxic T but not helper T cells
Fung-Leung, W.-P., Schilham, M. W., Rahemtulla, A., Kündig, T. M., Vollenweider, M., Potter, J., van Ewijk, W., & Mak, T. W. (1991) · Cell · doi:10.1016/0092-8674(91)90462-8 · Cited by 529
Immune function in mice lacking the perforin gene.
Walsh, C. M., Matloubian, M., Liu, C. C., Ueda, R., Kurahara, C. G., Christensen, J. L., Huang, M. T., Young, J. D., Ahmed, R., & Clark, W. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.10854 · Cited by 459
Sheehan, K. C. F., Ruddle, N. H., & Schreiber, R. D. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.11.3884 · Cited by 379
Braun, M. Y., Lowin, B., French, L., Acha-Orbea, H., & Tschopp, J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.2.657 · Cited by 297
Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes
Kojima, H., Shinohara, N., Hanaoka, S., Someya-Shirota, Y., Takagaki, Y., Ohno, H., Saito, T., Katayama, T., Yagita, H., Okumura, K., et al. (1994) · Immunity · doi:10.1016/1074-7613(94)90066-3 · Cited by 290
Kägi, D., Seiler, P., Pavlovic, J., Ledermann, B., Bürki, K., Zinkernagel, R. M., & Hengartner, H. (1995) · European Journal of Immunology · doi:10.1002/eji.1830251209 · Cited by 278
Self-citationTumor Eradication by Adoptive Transfer of Cytototic T Lymphocytes
(1992) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60294-8 · Cited by 275
Owen‐Schaub, L. B., Radinsky, R., Kruzel, E., Berry, K. K., & Yonehara, S. (1994) · PubMed · Cited by 258
Uyttenhove, C., Maryanski, J., & Boon, T. (1983) · The Journal of experimental medicine · doi:10.1084/jem.157.3.1040 · Cited by 245
Kägi, D., Ledermann, B., Bürki, K., Hengartner, H., & Zinkernagel, R. M. (1994) · European Journal of Immunology · doi:10.1002/eji.1830241223 · Cited by 226
Self-citationVaccinia Virus Recombinants: Expression of VSV Genes and Protective Immunization of Mice and Cattle
Mackett, M., Yilma, T., Rose, J. K., & Moss, B. (1985) · Science · doi:10.1126/science.2981435 · Cited by 221
Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes
Pel, A. V., Van Der Bruggen, P., Coulie, P. G., Brichard, V. G., Lethéa, B., Van Den Eynde, B., Uyttenhove, C., Renauld, J., & Boon, T. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00084.x · Cited by 218
Perforin dependence of natural killer cell‐mediated tumor control in vivo
van den Broek, M. F., Kägi, D., Zinkernagel, R. M., & Hengartner, H. (1995) · European Journal of Immunology · doi:10.1002/eji.1830251246 · Cited by 171
Self-citationLi, Y., McGowan, P., Hellström, I., Hellström, K. E., & Chen, L. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.1.421 · Cited by 137
Smith, M. E., Marsh, S. G. E., Bodmer, J. G., Gelsthorpe, K., & Bodmer, W. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.14.5557 · Cited by 122
Kägi, D., Odermatt, B., Ohashi, P. S., Zinkernagel, R. M., & Hengartner, H. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.5.2143 · Cited by 118
Self-citationThe Murine Sarcoma Virus-Induced Tumor: Exception or General Model in Tumor Immunology?
Lévy, J. P., & Leclerc, J. C. (1977) · Advances in cancer research · doi:10.1016/s0065-230x(08)61012-x · Cited by 108
Puddington, L., Bevan, M. J., Rose, J. K., & Lefrançois, L. (1986) · Journal of Virology · doi:10.1128/jvi.60.2.708-717.1986 · Cited by 101
Ehl, S. R., Hoffmann‐Rohrer, U., Nagata, S., Hengartner, H., & Zinkernagel, R. M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.7.2357 · Cited by 64
Self-citation
Cited by
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Paradoxical roles of the immune system during cancer development
de Visser, K. E., Eichten, A., & Coussens, L. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1782 · Cited by 2,256
Metadata
- Authors
- van den Broek, M. E., Kägi, D., Ossendorp, F., Toes, R., Vamvakas, S., Lutz, W. K., Melief, C. J., Zinkernagel, R. M., & Hengartner, H.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1996-11-01
- Volume
- 184
- Issue
- 5
- Pages
- 1781-1790
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2109721791
- Cited by
- 512
- References
- 31
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.